- Home
- CEV vs IOBT Comparison
CEV vs IOBT Comparison
Compare CEV & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEV | IOBT |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.8M | 57.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CEV | IOBT |
|---|---|---|
| Price | $10.11 | $0.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 19.6K | ★ 805.8K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.83 | $0.32 |
| 52 Week High | $10.91 | $2.79 |
Technical Indicators
Market Signals| Indicator | CEV | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 34.00 | 45.53 |
| Support Level | $10.14 | $0.61 |
| Resistance Level | $10.21 | $0.72 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 9.10 | 32.14 |
Price Performance
Historical ComparisonAbout CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.